C9300 — Injection, indigotindisulfonate sodium, 1 mg
C9300 is a HCPCS Level II code for injection, indigotindisulfonate sodium, 1 mg. It belongs to the Outpatient Prospective Payment System section. It was terminated on June 30, 2025 and is not valid on new claims.
This code has been terminated
CMS terminated C9300 on June 30, 2025. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Special coverage instructions apply
There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
The CMS record for C9300
- Long descriptor
- Injection, indigotindisulfonate sodium, 1 mg
- Short descriptor
- Indigotindisulfonate, 1 mg
- Added
- April 1, 2025
- Terminated
- June 30, 2025
- BETOS
- O1E
- Pricing indicator
- 53 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Statute.
Codes adjacent to C9300
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If C9300 is not quite right, the correct code is very often within a few positions of it.
- C9248Injection, clevidipine butyrate, 1 mgterminated
- C9250Human plasma fibrin sealant, vapor-heated, solvent-detergent (artiss), 2 ml
- C9254Injection, lacosamide, 1 mg
- C9257Injection, bevacizumab, 0.25 mg
- C9275Injection, hexaminolevulinate hydrochloride, 100 mg, per study doseterminated
- C9285Lidocaine 70 mg/tetracaine 70 mg, per patch
- C9290Injection, bupivacaine liposome, 1 mgterminated
- C9293Injection, glucarpidase, 10 units
- C9301Obecabtagene autoleucel, up to 400 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic doseterminated
- C9302Injection, zanidatamab-hrii, 2 mgterminated
- C9303Injection, zolbetuximab-clzb, 1 mgterminated
- C9304Injection, marstacimab-hncq, 0.5 mgterminated
- C9305Injection, nipocalimab-aahu, 3 mgterminated
- C9306Injection, telisotuzumab vedotin-tllv, 1 mgterminated
- C9307Injection, linvoseltamab-gcpt, 1 mgterminated
- C9308Injection, carboplatin (avyxa), 1 mgterminated
Questions about C9300
What is HCPCS code C9300?
C9300 is a HCPCS Level II code for injection, indigotindisulfonate sodium, 1 mg. It sits in the Outpatient Prospective Payment System section.
Does Medicare cover C9300?
The CMS HCPCS file marks C9300 as "Special coverage instructions apply". There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
Is C9300 still valid?
No. C9300 was terminated on June 30, 2025 and should not be used on new claims.